Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE filing · raw filing ↗
15 Aug 2026
⚑ Filing
Copy of Newspaper PublicationNSE filing · raw filing ↗
13 Aug 2026
⚑ Filing
Glenmark Pharmaceuticals Ltd - 532296 - Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual ReportBSE filing · raw filing ↗
Glenmark Pharmaceuticals Ltd - 532296 - Notice Of The 48Th Annual General Meeting For The Financial Year 2025-26BSE filing · raw filing ↗
11 Aug 2026
⚑ Filing
Glenmark Pharmaceuticals Ltd - 532296 - Settlement Agreement - Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015BSE filing · raw filing ↗
Q4 FY26 results filed — revenue ₹3,771 Cr (+15.8% YoY), PAT ₹301 Cr (−NaN% YoY)NSE filing · raw filing ↗
29 May 2026
⚑ Filing
Analysts/Institutional Investor Meet/Con. Call UpdatesNSE filing · raw filing ↗
23 May 2026
⚑ Filing
Analysts/Institutional Investor Meet/Con. Call UpdatesNSE filing · raw filing ↗
Ex-date 3 Oct 2025
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing · record 3 Oct 2025
Ex-date 15 Sep 2025
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing · record 15 Sep 2025
Ex-date 13 Sep 2024
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing
Ex-date 18 Sep 2023
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing
Ex-date 12 Sep 2022
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing
Ex-date 8 Sep 2021
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing
Ex-date 17 Sep 2020
⚑ Corp action
Dividend — ₹2.50 per shareNSE filing
Ex-date 19 Sep 2019
⚑ Corp action
Dividend — ₹2.00 per shareNSE filing
Ex-date 19 Sep 2018
⚑ Corp action
Dividend — ₹2.00 per shareNSE filing
Ex-date 20 Sep 2017
⚑ Corp action
Dividend — ₹2.00 per shareNSE filing
Ex-date 3 Aug 2016
⚑ Corp action
Dividend — ₹2.00 per shareNSE filing
Ex-date 10 Sep 2015
⚑ Corp action
Dividend — ₹2.00 per shareNSE filing
NOT BUILT YETPer-item summaries & sentiment — not built yetOne-line plain-language summaries and a sentiment read of every filing. Not built yet. When they exist they will describe — never advise.
Official filings & corporate actions · newest first
